Clinical and patient-reported outcomes affirm high quality-vision, patient satisfaction and increased spectacle independence of next-generation lens, with 96.8% of patients reporting spectacle independence for distancei
Study selected for presentation in the official media programme at ESCRS 2025
LIMERICK, IRELAND, 14 September 2025 – Johnson & Johnson*, a global leader in eye health, today announced new real-world findings supporting the performance of the TECNIS PureSee™ intraocular lens (IOL), a purely refractive, presbyopia-correcting IOLii. These initial resultsiii, presented by study author, Dr. Oliver Findl, will be featured in the official media programme at the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), highlighting its significance to the ophthalmology community.
“Since debuting on this global stage last year, TECNIS PureSee™ IOL has gained significant traction worldwide, offering important benefits to both surgeons and their patients with presbyopia,” said Jacqueline Henderson, President, EMEA, Vision at Johnson & Johnson. “With over 250,000 implants to date, this latest real-world data reinforces the IOL’s strong clinical performance and outstanding patient outcomes. Together with the TECNIS Odyssey IOL, we are expanding our portfolio to offer greater choices and personalized solutions to address the evolving presbyopia needs of today’s cataract patients.”
The ongoing, multicentre, single-arm, single-visit, observational study (ESCRS25-FP-2396, Extended Depth of Field IOL, Sunday, 14 September 2025 at 14:00 - 15:30) evaluated visual acuity at various distances and assessed patient-reported outcomes in patients bilaterally implanted with TECNIS PureSee IOL. Conducted across nine sites in Europe and the Asia-Pacific region, the study reflects real-world clinical practice and patient experience, involving 95 patients to date.
Key findings from the study, which deepen understanding of patient outcomes, include:
- Strong visual outcomes across distances: Patients achieved excellent distance vision, very good intermediate vision and functional near vision.
- Mean post-operative refraction spherical equivalent (MRSE) was 0.10 ±0.41 D. Mean logMAR binocular best-corrected distance visual acuity (BCDVA), distance-corrected intermediate VA (DCIVA, 66 cm)) and distance-corrected near VA (DCNVA, 40cm) were -0.09 ± 0.08, 0.12 ± 0.10, and 0.24 ± 0.14, respectively. Binocularly, 91.5% of subjects achieved 0.2 logMAR or better DCIVA and 71.3% achieved 0.3 logMAR or better DCNVA.
- High levels of spectacle independence: A large majority of patients reported needing glasses “none” or “a little of the time” for distance (96.8%), intermediate (94.7%), near (58.9%) and overall vision (86.3%).
- Strong patient satisfaction and lens recommendation: Most patients were “mostly” or “completely” satisfied with their distance (93.7%), intermediate (94.7%), near (62.1%) and overall vision (91.6%) and would recommend the lens to their family and friends (93.7%).
“The TECNIS PureSee IOL has become a valuable part of my cataract practice, providing continuous, high-quality vison from far to functional near without visual interruptions,”iv,v said Dr. Oliver Findl, MD, MBA, Chair of Department of Ophthalmology, Hanusch Hospital Vienna and ESCRS Past President.** “These real-world results mirror what we see in daily clinical practice: reliable outcomes and satisfied patients. I’m pleased to see this research recognized in the ESCRS media programme.”
For additional information about J&J’s presence at the 2025 ESCRS Conference, please visit https://eur.cvent.me/5VWkRg
With a variety of options for different visual needs and lifestyles, the TECNIS platform empowers more patients to find the right solution. The Johnson & Johnson portfolio of advanced Presbyopia Correction IOLs available in Europe, the Middle East, Canada, and Japan now includes both TECNIS Odyssey IOL, the new full visual range IOL,***vi and TECNIS PureSee™ IOL. TECNIS Odyssey IOL, the full range of vision IOL, is also available in the US, Puerto Rico, and Japan. TECNIS PureSee IOL is also available across APAC and Latin America. TECNIS PureSee™ IOL has not received PMA Approval in the U.S.
###
About Vision at Johnson & Johnson
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients' eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionising the way people see and experience the world. Visit us at jnjvisionpro.eu and follow Johnson & Johnson | Vision EMEA on LinkedIn.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to TECNIS PureSee™ IOL platform. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realised or may take longer to realise than expected; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Footnotes
*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
**Paid consultant of Vision at Johnson & Johnson. Dr Findl was not paid for his quote.
***According to ISO 11979-7:2024, based on the clinical study of the parent IOL.
The promoted product is a medical device. For healthcare professionals only. Please reference the Instructions for Use for a complete list of Indications and Important Safety Information and contact our specialists in case of any question.
©Johnson & Johnson and its affiliates 2025. All rights reserved. Third party trademarks are the property of their respective owners.
2025PP13671
- Findl, O., Cheng, D., ESCRS25-FP-2396 Abstract. Spectacle Independence And Visual Outcomes In Patients Bilaterally Implanted With A Purely Refractive Extended Depth Of Focus Presbyopia Correcting Intraocular Lens. A Multicentre Observational Study, ESCRS 2025.
- TECNIS PureSee™ OptiBlue™ IOL, Model ZEN00V, DfU INT, Z311973, current revision.
- Findl, O., Cheng, D., ESCRS25-FP-2396 Abstract. Spectacle Independence And Visual Outcomes In Patients Bilaterally Implanted With A Purely Refractive Extended Depth Of Focus Presbyopia Correcting Intraocular Lens. A Multicentre Observational Study, ESCRS 2025.
- DOF2023CT4016 – Simulated VA of the TECNIS PureSee™IOL compared to TECNIS Eyhance™ and TECNIS™ 1-Piece IOL. 29 March 2023.
- DOF2023CT4027 Simulated VA of the TECNIS PureSee™ IOL compared to TECNIS Symfony™ IOL. 15 March 2023.
- Data on File. 2024DOF4002 (prospective, multicenter, randomized, three-way-masked clinical study comparing subjects bilaterally implanted with TECNIS Synergy IOL (n=132) vs TECNIS 1-Piece Monofocal IOL (n=131) at 6-months post-op).
Media contact:
Sarah Smith
[email protected]
+44 7920 082012